Announcing Earth Day Plus (Apr 22 to May 3) – VC-Founder Matchup + Live Sessions. Learn More

Laguna Biotherapeutics

Next generation bispecific antibody cancer therapy.

Team

Jonathan Kotula

CEO & Co-Founder

Russell Carrington

Co-Founder

Company details

More info at the IndieBio website

We have shown in people that our technology expands and activates gamma delta T cells, up to 10,000x better than other known approaches. This profound and durable effect can be harnessed as a monotherapy, or in combination with bispecific T cell engagers (BiTEs). We are at the seed stage with human clinical data to support our approach, significant IP protection, and traction with pharma partners to generate early clinical validation with their bispecific antibodies.

Get In Touch with Laguna Biotherapeutics

Please tell us a little bit about yourself and why you'd like to get connected. Laguna Biotherapeutics + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.